关注乙型肝炎肝硬化患者的肾脏问题

doi:10.3969/j.issn.1672-5069.2015.05.003

Abstract

Zhang Di, Li Liangping. Kidney problems in patients with hepatitis B cirrhosis during antiviral therapy[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2015, 18(5): 457-459.

[1] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南（2010年版）. 实用肝脏病杂志，2011，14（2）：81-89.
[2] 亚太肝病学会慢性乙型肝炎治疗共识工作组. 亚太地区慢性乙型肝炎治疗共识（2012最新版）. 临床肝胆病杂志，2012，28（8）:I-XXI.
[3] European Association for the Study of the Liver. EASL clinical practice guidelines:management of chronic hepatitis B virus infection. J Hepatol，2012.57（1）:167-185.
[4] Anna SF，McMahon LB. Chronic hepatitis B:Update 2009. Hepatology，2009，50（3）:1-34.
[5] Sun FX，Lu Z. Renal dysfunction analysis in 298 patients with HBV-associated liver cirrhosis. APASL，2014，post 1841.
[6] FernaAndez-Esparrach G，SaAnchez-Fueyo1 A. A prognostic model for predicting survival in cirrhosis with ascites. J Hepatol，2001，34（1）:46-52.
[7] Lim YS，Larson TS. Serum sodium，renal function，and survival of patients with end-stage liver disease. J Hepatol，2010，52（4）:523-528.
[8] Gara N，Zhao X，Collins MT，et al． Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B． Aliment Pharmacol Ther，2012，35（11）:1317-1325．
[9] Fontana RJ. Entecavir in decompensated HBV cirrhosis:The future is looking brighter. J Hepatol，2010，52（2）:147-149.
[10] Schiff E，Lai CL，Hadziyannis S，et al. Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B:final long-term results. Liver Transpl，2007，13（2）:349-360.
[11] Liaw YF，Raptopoulou-Gigi M. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation:a randomized， open-label study. Hepatology，2011，54（1）:91-100.
[12] Liaw YF，Sheen IS，Lee CM，et al. Tenofovir disoproxil fumarate （TDF），emtricitabine/TDF，and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology，2011，53（1）:62-72.
[13] Fang J.Impact of oral nucleos（t）ide analogues on renal function in chronic hepatitis B patients，Hepatology，2014，60（S1）:S1-S405，Abstract#223.
[14] Lesi O，McMahon B. Guidelines for the prevention，care and treatment of persons with chronic hepatitis B infection. The World Health Organization are available on the WHO website. MARCH 2015:xxiv.
[15] Gane E，Deray G，Piratvisuth T，et al． Renal function of chronic hepatitis B（CHB） patients improves with telbivudine treatment．Thailand，Bangkok:APASL，2011．
[16] Liaw YF，Gane E，Leung N，et al. 2-Year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis B． Gastroenterology，2009，136（2）:486-495．
[17] Gane EJ，Deray G，Liaw YF，et al． Telbivudine improves renal function in patients with chronic hepatitis B． Gastroenterology，2014，146（1）:138-146．
18] 欧蔚妮，赵莹莹，魏丽荣，等. 替比夫定治疗对慢性乙型肝炎患者肾小球滤过率的影响及相关因素分析. 中华实验和临床感染病杂志：电子版，2013，7（6）:855-859.
[19] Chan LY，Chen YC. Randomized clinical trial:efficacy and safety of telbivudine and lamivudine in treatment-naive patients with HBV-related decompensated cirrhosis. J Viral Hepat，2012，19（10），732-743.
[20] Piratvisuth T，Komolmit P. 2-year results of telbivudine roadmap study verify the optimal efficacy and safety results in HBeAg positive chronic hepatitis B patients. J Hepatol，2012，56（S2）:S214.
[21] Sun J，Xie Q，Tan D，et al． The 104-week efficacy and safety of telbivudine-based optimization strategy in chronic hepatitis B patients:a randomized，controlled study. Hepatology，2014，59（4）:1283－1292．
[22] Lee MJ，Sohee OH. Telbivudline protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. APASL 2014，poster 182.
[23] Gane E，Amarapurkar D． Telbivdine treatment effect on glomerular filtration rate in chronic hepatitis B patients with potential risks of renal dysfunction. J Hepatol，2012，56（1）:S200-S201.
[24] 王宇，欧晓娟，马红. 替比夫定对慢性乙型肝炎患者肾功能的影响. 临床和实验医学杂志，2015，14（4）:336-339.

Kidney problems in patients with hepatitis B cirrhosis during antiviral therapy

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhuang Ying, Lin Zhihui.. Clinical manifestations and diagnosis of portal vein thrombosis [J]. Journal of Practical Hepatology, 2019, 22(6): 765-767.
[2]	chronic hepatitis B Zhu Lingyun, Zhang Maohai Cui Shasha, et al.. Serum IL-12 and IL-18 levels as well as peripheral blood mononuclear cell FOXp3 in patients with [J]. Journal of Practical Hepatology, 2019, 22(6): 816-819.
[3]	Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.
[4]	Min Feng, Huang Wenqi, Wu Weibing, et al.. Implications of serum adipocytokine levels in patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(6): 824-827.
[5]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[6]	chronic hepatitis B virus carriers Wu Haiyi, Chen Jianxin.. Diagnostic efficacy of four non-invasive diagnostic models in evaluating significant liver fibrosis in [J]. Journal of Practical Hepatology, 2019, 22(6): 832-835.
[7]	Ma Liying, Shen Lijuan.. Efficacy and safety of tenofovir in the treatment of pregnant women with high HBV DNA loads [J]. Journal of Practical Hepatology, 2019, 22(6): 836-839.
[8]	Yang Caiyong, Chen Na, Li Kui, et al.. Clinical significance of peripheral blood Treg and Th17 cells in patients with chronic hepatitis C and hepatitis C-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 868-871.
[9]	Wu Dan Ma Xiangying.. Insulin resistance,carotid atherosclerosis and left ventricular function in patients with NAFLD-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2019, 22(6): 876-879.
[10]	He Zhi’an, Yu Liping, Lai Jiangqiong, et al.. Evaluation of varices bleeding and portal vein thrombosis by ARFI in patients with cirrhosis and esophagogastric varices [J]. Journal of Practical Hepatology, 2019, 22(6): 888-891.
[11]	Li Chuanjie, Xu Jing, Wang Liangliang, et al.. Changes of serum HBsAg levels in patients with chronic hepatitis B receiving entecavir treatment [J]. Journal of Practical Hepatology, 2019, 22(6): 928-929.
[12]	Du Keye, Yang Dongliang, Liu Jia. Regulatory T cells in hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 613-616.
[13]	Liao Guichan, Peng Jie, Zhang Xiaoyong. Roles of hepatocytes in intrinsic innate immunity in control of hepatits B virus infection [J]. Journal of Practical Hepatology, 2019, 22(5): 617-619.
[14]	Zhao Xieshan, Wu Chunrong, Wang Chunfeng, et al. Preliminary study on the efficacy of combination of tenofovir and Anluo Huaxian pill in the treatment of patients with HBeAg-negative chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 644-647.
[15]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.